This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In the article “Evidence in focus: Nusinersen use in spinal muscular atrophy,” Michelson et al. systematically reviewed 4 published clinical trials of nusinersen for patients with spinal muscular atrophy (SMA) and concluded that the evidence is highest for treatment of infantile- and childhood-onset SMA in the early and middle symptomatic phases. In response, Takanashi et al. note that although no life-threatening adverse events were reported in the trials, 5 patients were noted to have communicating hydrocephalus. They present a 6-month-old boy with SMA type 1 who developed communicating hydrocephalus in temporal association with nusinersen treatment that subsequently improved with ventriculoperitoneal shunting. They conclude that communicating hydrocephalus is a rare but serious adverse event in nusinersen treatment. However, the authors of the article did not respond to this comment.
In the article “Evidence in focus: Nusinersen use in spinal muscular atrophy,” Michelson et al. systematically reviewed 4 published clinical trials of nusinersen for patients with spinal muscular atrophy (SMA) and concluded that the evidence is highest for treatment of infantile- and childhood-onset SMA in the early and middle symptomatic phases.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Evidence in focus: Nusinersen use in spinal muscular atrophy
Reader response: Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
Nusinersen in later-onset spinal muscular atrophy
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy